Pancreas Cancer | GOFURTGO Trial (AG0503P)
Phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5-FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Schema
.gif)
Summary
Many patients diagnosed with cancer of the pancreas present late with tumours that are already locally advanced and usually not removable by surgery. This phase II study will evaluate the activity and toxicity of chemoradiation after initial chemotherapy and before consolidation chemotherapy with gemcitabine and oxaliplatin. Based on the results achieved in this study, the AGITG aims to test the best regimen in a future phase III study comparing it with an accepted standard regimen.
